Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE4
Total Enrollment
240 participants
Study Classification
INTERVENTIONAL
Study Start Date
2022-04-13
Study Completion Date
2025-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This study aims to evaluate the impact of simvastatin on the bone density of postmenopausal women with type 2 diabetes over a duration of 18 months, using a randomized controlled trial design. Aiming to recruit 240 patients, half of them will be randomly assigned to receive simvastatin treatment, while the other half will receive ezetimibe, also a lipid-lowering agent with no known effect on bone. Bone density will be measured at the baseline and the end of the study for comparison of the changes between the simvastatin and the ezetimibe groups.
This is an investigator-initiated study. The principal investigator and the study team will be responsible for ensuring that the study is conducted in compliance with this protocol and the study data collected are verified against the relevant source documents.
All participants will undergo clinical and biochemical assessments at baseline of the trial. Participants will be seen by an endocrinologist at baseline and subsequent follow-up visits at 3, 6, 12 and 18 months respectively.
This is an investigator-initiated study. The principal investigator and the study team will be responsible for ensuring that the study is conducted in compliance with this protocol and the study data collected are verified against the relevant source documents.
All participants will undergo clinical and biochemical assessments at baseline of the trial. Participants will be seen by an endocrinologist at baseline and subsequent follow-up visits at 3, 6, 12 and 18 months respectively.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
TST002 Intervenous Injection in Postmenopausal Women and Men With Reduced Bone Mineral Density
NCT05391776
Osteoporosis
UNKNOWN
PHASE1
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes
NCT00471549
Type 2 Diabetes
COMPLETED
PHASE4
Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMD
NCT00577837
Postmenopausal
COMPLETED
PHASE2
A Study of SB751689 in Japanese Postmenopausal Women
NCT00554255
Osteoporosis
COMPLETED
PHASE1
Risedronate in Postmenopausal Women With Low Bone Density
NCT00351091
OSTEOPOROSIS, POSTMENOPAUSAL
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Study Procedures and Assessments Screening Procedures
Patients will be recruited from medical out-patient clinics, mainly from the primary health care clinics, in the Hong Kong West Cluster of the Hong Kong Hospital Authority. Consecutive participants who fulfil the inclusion and exclusion criteria are invited to participate in this randomized controlled trial after obtaining informed consent.
Clinical and biochemical assessments
Participants will attend a clinical assessment session at baseline after an overnight fast for at least 8 hours. Demographic data and medical history will be obtained using a standardized questionnaire. Personal and family history of fragility fractures (spine, hip, humerus, wrist and ankle) will be recorded. Important clinical risk factors of osteoporosis will be evaluated, including smoking, drinking, family history of fragility fractures, parental history of hip fractures, prior use and duration of hormonal replacement therapy, and levels of physical activity. The levels of physical activity will be assessed through the International Physical Activity Questionnaire (IPAQ). Daily calcium intake will be assessed using a semi-quantitative questionnaire. Body weight, body height and blood pressure (BP) will be measured. Hypertension is defined as BP ≥140/90 mmHg or the use of antihypertensive medications.
Fasting blood will be drawn for plasma glucose, HbA1c, insulin, lipid profile, albumin, calcium, phosphate, creatinine levels and eGFR. Patients with 25OHD levels \<50 nmol/L will be given additional cholecalciferol 1000 units/day for 8 weeks followed by reassessment of 25-hydroxyvitamin D (25OHD) to ensure repletion.
Follow-up visits (3, 6, 12, 18 months after baseline visit)
During each follow-up visits, participants will have fasting blood tests checked for liver and renal function tests, creatine kinase, calcium and phosphate, fasting glucose, HbA1c and lipid profile.
Glycaemic control will be managed according to the standard of care. During follow-up visits, tolerance to lipid-lowering therapy will be assessed. Persistent elevation of liver enzymes (alanine aminotransferase and aspartate aminotransferase) to \>3 times the upper limit of normal, increase in creatine kinase with clinical signs and symptoms of muscle involvement, or drug intolerance will be excluded from the trial.
During follow-up visits, participants may have changes in clinical conditions and thus be indicated for anti-osteoporosis therapy, or higher-intensity statin. Those who develop incident hip or vertebral fractures, or osteoporosis, and thus require anti-osteoporosis therapy, will be excluded from the trial. Those who develop incident atherosclerotic cardiovascular disease, and thus require higher intensity statin, will also be excluded from the trial.
Withdrawal from study
Patients are informed orally and in writing that they are free to withdraw their participation in the study without bias or prejudice. A patient who decides to stop all therapeutic interventions will be followed by the clinical team for the usual medical care. The date of withdrawal and reason for discontinuation, if known, will be recorded in the medical record.
Statistical Analyses
All statistical analyses will be performed with using R package or IBM® SPSS® version 26. Data will be presented as mean± standard deviation (SD), 95% confidence interval (CI), median with 25th-75th percentile, and number with percentage as appropriate.
All analyses described in this section will be performed based on intention-to-treat analysis and repeated for the per-protocol analysis. Data not normally distributed will be logarithmically transformed before analysis. Between-group comparisons are done with t-test or Mann-Whitney U test for continuous data, and chi-square or Fisher exact test for categorical variables. Two-sided p-value \<0.05 will be considered statistically significant.
Baseline demographics and anthropometric parameters (age, BMI), laboratory parameters (HbA1c, LDL-cholesterol, serum creatinine), bone health assessment, including bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers and fracture risk assessment (FRAX) score, clinical risk factors of osteoporosis, family history of fragility fractures (partly reflecting involvement of genetics in bone health), and concomitant medications (various classes of anti-hypertensives and anti-diabetic agents) will be compared between simvastatin and ezetimibe arms.
If applicable, adjustments for covariates may be employed in Analysis of Covariance (ANCOVA). Any adjustments will be pre-specified in the description of the analysis.
BMD is measured with a dual-energy X-ray absorptiometry (DXA) machine (Hologic QDR 4500, Waltham, MA, USA). BMD change over the 18-month period will be calculated for each participant. The BMD change over the lumbar spine (LS), femoral neck (FN), total hip (TH) and distal radius from baseline will be the dependent variable in the ANCOVA model.
Sample size calculation
Sample size calculation is performed with R package (1). According to the study on the impact of lovastatin on TH BMD by Safaei et al. (2), a difference in BMD change over 18-month study period between lovastatin-treated and control groups was 0.098 g/cm2 for TH, with a pooled standard deviation of 0.13 g/cm2. The estimated effect size of TH BMD change over the 18-month study period is 0.75 (95% CI: 0.2-1.3). Assuming the lower CI for the estimated effect size of 0.2, the study would require a sample size of 96 in each group (i.e. total sample size of 192), to achieve 90% power and a level of significance of 5%, for declaring that simvastatin is superior to the active comparator at a 0.02 g/cm2 margin of superiority. To ensure an analysis size of 96 individuals, an overall sample size of 120 individuals per treatment arm will be recruited, anticipating a drop-out rate of approximately 20%.
Protocol Deviations
Protocol deviations are defined as any instance in which the patient or clinical team does not perform scheduled activities/tasks such as missed visits and missed tests and evaluations. Protocols deviations will be reported on the patient's chart.
Patients will be recruited from medical out-patient clinics, mainly from the primary health care clinics, in the Hong Kong West Cluster of the Hong Kong Hospital Authority. Consecutive participants who fulfil the inclusion and exclusion criteria are invited to participate in this randomized controlled trial after obtaining informed consent.
Clinical and biochemical assessments
Participants will attend a clinical assessment session at baseline after an overnight fast for at least 8 hours. Demographic data and medical history will be obtained using a standardized questionnaire. Personal and family history of fragility fractures (spine, hip, humerus, wrist and ankle) will be recorded. Important clinical risk factors of osteoporosis will be evaluated, including smoking, drinking, family history of fragility fractures, parental history of hip fractures, prior use and duration of hormonal replacement therapy, and levels of physical activity. The levels of physical activity will be assessed through the International Physical Activity Questionnaire (IPAQ). Daily calcium intake will be assessed using a semi-quantitative questionnaire. Body weight, body height and blood pressure (BP) will be measured. Hypertension is defined as BP ≥140/90 mmHg or the use of antihypertensive medications.
Fasting blood will be drawn for plasma glucose, HbA1c, insulin, lipid profile, albumin, calcium, phosphate, creatinine levels and eGFR. Patients with 25OHD levels \<50 nmol/L will be given additional cholecalciferol 1000 units/day for 8 weeks followed by reassessment of 25-hydroxyvitamin D (25OHD) to ensure repletion.
Follow-up visits (3, 6, 12, 18 months after baseline visit)
During each follow-up visits, participants will have fasting blood tests checked for liver and renal function tests, creatine kinase, calcium and phosphate, fasting glucose, HbA1c and lipid profile.
Glycaemic control will be managed according to the standard of care. During follow-up visits, tolerance to lipid-lowering therapy will be assessed. Persistent elevation of liver enzymes (alanine aminotransferase and aspartate aminotransferase) to \>3 times the upper limit of normal, increase in creatine kinase with clinical signs and symptoms of muscle involvement, or drug intolerance will be excluded from the trial.
During follow-up visits, participants may have changes in clinical conditions and thus be indicated for anti-osteoporosis therapy, or higher-intensity statin. Those who develop incident hip or vertebral fractures, or osteoporosis, and thus require anti-osteoporosis therapy, will be excluded from the trial. Those who develop incident atherosclerotic cardiovascular disease, and thus require higher intensity statin, will also be excluded from the trial.
Withdrawal from study
Patients are informed orally and in writing that they are free to withdraw their participation in the study without bias or prejudice. A patient who decides to stop all therapeutic interventions will be followed by the clinical team for the usual medical care. The date of withdrawal and reason for discontinuation, if known, will be recorded in the medical record.
Statistical Analyses
All statistical analyses will be performed with using R package or IBM® SPSS® version 26. Data will be presented as mean± standard deviation (SD), 95% confidence interval (CI), median with 25th-75th percentile, and number with percentage as appropriate.
All analyses described in this section will be performed based on intention-to-treat analysis and repeated for the per-protocol analysis. Data not normally distributed will be logarithmically transformed before analysis. Between-group comparisons are done with t-test or Mann-Whitney U test for continuous data, and chi-square or Fisher exact test for categorical variables. Two-sided p-value \<0.05 will be considered statistically significant.
Baseline demographics and anthropometric parameters (age, BMI), laboratory parameters (HbA1c, LDL-cholesterol, serum creatinine), bone health assessment, including bone mineral density (BMD), trabecular bone score (TBS), bone turnover markers and fracture risk assessment (FRAX) score, clinical risk factors of osteoporosis, family history of fragility fractures (partly reflecting involvement of genetics in bone health), and concomitant medications (various classes of anti-hypertensives and anti-diabetic agents) will be compared between simvastatin and ezetimibe arms.
If applicable, adjustments for covariates may be employed in Analysis of Covariance (ANCOVA). Any adjustments will be pre-specified in the description of the analysis.
BMD is measured with a dual-energy X-ray absorptiometry (DXA) machine (Hologic QDR 4500, Waltham, MA, USA). BMD change over the 18-month period will be calculated for each participant. The BMD change over the lumbar spine (LS), femoral neck (FN), total hip (TH) and distal radius from baseline will be the dependent variable in the ANCOVA model.
Sample size calculation
Sample size calculation is performed with R package (1). According to the study on the impact of lovastatin on TH BMD by Safaei et al. (2), a difference in BMD change over 18-month study period between lovastatin-treated and control groups was 0.098 g/cm2 for TH, with a pooled standard deviation of 0.13 g/cm2. The estimated effect size of TH BMD change over the 18-month study period is 0.75 (95% CI: 0.2-1.3). Assuming the lower CI for the estimated effect size of 0.2, the study would require a sample size of 96 in each group (i.e. total sample size of 192), to achieve 90% power and a level of significance of 5%, for declaring that simvastatin is superior to the active comparator at a 0.02 g/cm2 margin of superiority. To ensure an analysis size of 96 individuals, an overall sample size of 120 individuals per treatment arm will be recruited, anticipating a drop-out rate of approximately 20%.
Protocol Deviations
Protocol deviations are defined as any instance in which the patient or clinical team does not perform scheduled activities/tasks such as missed visits and missed tests and evaluations. Protocols deviations will be reported on the patient's chart.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Diabetes Mellitus, Type 2
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Eligible participants will be randomly allocated 1:1 to 18 months of simvastatin 10mg/day or ezetimibe 10mg/day.
Primary Study Purpose
HEALTH_SERVICES_RESEARCH
Blinding Strategy
DOUBLE
Participants
Investigators
The computer-generated sequence will be supplied by the study statistician, independent of the investigators. To facilitate double-blinding, placebo tablets with the same shapes as simvastatin 10mg and ezetimibe 10mg, respectively.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Simvastatin 10mg/day
One simvastatin 10mg-tablet and one placebo tablet with the shape of ezetimibe 10mg each day.
Group Type
EXPERIMENTAL
Simvastatin 10mg
Intervention Type
DRUG
One simvastatin 10mg-tablet
Ezetimibe 10mg/day
One ezetimibe 10mg-tablet and one placebo tablet with the shape of simvastatin 10mg each day.
Group Type
ACTIVE_COMPARATOR
Ezetimibe 10mg
Intervention Type
DRUG
One ezetimibe 10mg-tablet
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Simvastatin 10mg
One simvastatin 10mg-tablet
Intervention Type
DRUG
Ezetimibe 10mg
One ezetimibe 10mg-tablet
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Chinese women
* Aged 50 to 74 years (inclusive);
* Type 2 diabetes Mellitus;
* Postmenopausal: confirmed with the last menstrual period \>12 months by the time of recruitment into the study
* Aged 50 to 74 years (inclusive);
* Type 2 diabetes Mellitus;
* Postmenopausal: confirmed with the last menstrual period \>12 months by the time of recruitment into the study
Exclusion Criteria
* Entry HbA1c \>8.5%;
* On thiazolidinedione;
* Baseline LDL-cholesterol \>3.0 mmol/L, triglyceride \>5.0 mmol/L, or known familial hypercholesterolaemia;
* History of hip and/or clinical vertebral fractures;
* Osteoporosis by BMD criteria on DXA;
* On anti-osteoporosis therapy within the prior 2 years;
* Evidence of secondary causes of osteoporosis including Cushing's syndrome, acromegaly, thyrotoxicosis, primary hyperparathyroidism, metabolic bone diseases (e.g. osteomalacia), and systemic glucocorticoid treatment;
* Evidence of documented ASCVD, which includes previous acute coronary syndrome, stable angina, coronary revascularization, stroke and transient ischaemic attack and peripheral arterial disease;
* On lipid-lowering therapy within the prior 2 years;
* Known contraindications to statin therapy including allergy, intolerance and significant liver function abnormality (alanine aminotransferase level \>3 times upper limit of normal);
* Significant diabetic complication(s): pre-proliferative / proliferative diabetic retinopathy, diabetic maculopathy, overt proteinuria, estimated glomerular filtration rate (eGFR) \<30 mL/min;
* Inability to give an informed consent
* On thiazolidinedione;
* Baseline LDL-cholesterol \>3.0 mmol/L, triglyceride \>5.0 mmol/L, or known familial hypercholesterolaemia;
* History of hip and/or clinical vertebral fractures;
* Osteoporosis by BMD criteria on DXA;
* On anti-osteoporosis therapy within the prior 2 years;
* Evidence of secondary causes of osteoporosis including Cushing's syndrome, acromegaly, thyrotoxicosis, primary hyperparathyroidism, metabolic bone diseases (e.g. osteomalacia), and systemic glucocorticoid treatment;
* Evidence of documented ASCVD, which includes previous acute coronary syndrome, stable angina, coronary revascularization, stroke and transient ischaemic attack and peripheral arterial disease;
* On lipid-lowering therapy within the prior 2 years;
* Known contraindications to statin therapy including allergy, intolerance and significant liver function abnormality (alanine aminotransferase level \>3 times upper limit of normal);
* Significant diabetic complication(s): pre-proliferative / proliferative diabetic retinopathy, diabetic maculopathy, overt proteinuria, estimated glomerular filtration rate (eGFR) \<30 mL/min;
* Inability to give an informed consent
Minimum Eligible Age
50 Years
Maximum Eligible Age
74 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Hong Kong
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Lui Tak Wai David
Clinical Assistant Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tak Wai David Lui, MD
Role: PRINCIPAL_INVESTIGATOR
The University of Hong Kong
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Diabetes Centre, 2/F, Block L, Department of Medicine, Queen Mary Hospital
Hong Kong, , Hong Kong
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Hong Kong
References
Explore related publications, articles, or registry entries linked to this study.
Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. 2008. 58 p.
Reference Type
BACKGROUND
Safaei H, Janghorbani M, Aminorroaya A, Amini M. Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus. Acta Diabetol. 2007 Jun;44(2):76-82. doi: 10.1007/s00592-007-0246-6. Epub 2007 May 27.
Reference Type
BACKGROUND
Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S. Major osteoporotic fragility fractures: Risk factor updates and societal impact. World J Orthop. 2016 Mar 18;7(3):171-81. doi: 10.5312/wjo.v7.i3.171. eCollection 2016 Mar 18.
Reference Type
BACKGROUND
Tatangelo G, Watts J, Lim K, Connaughton C, Abimanyi-Ochom J, Borgstrom F, Nicholson GC, Shore-Lorenti C, Stuart AL, Iuliano-Burns S, Seeman E, Prince R, March L, Cross M, Winzenberg T, Laslett LL, Duque G, Ebeling PR, Sanders KM. The Cost of Osteoporosis, Osteopenia, and Associated Fractures in Australia in 2017. J Bone Miner Res. 2019 Apr;34(4):616-625. doi: 10.1002/jbmr.3640. Epub 2019 Jan 7.
Reference Type
BACKGROUND
Lee PCH, Woo YC, Lam KSL. Fighting the Health Challenges of Diabetes in Hong Kong: A Window Into Mainland China. Am J Public Health. 2018 Dec;108(12):1623-1624. doi: 10.2105/AJPH.2018.304740. No abstract available.
Reference Type
BACKGROUND
55th EASD Annual Meeting of the European Association for the Study of Diabetes : Barcelona, Spain, 16 - 20 September 2019. Diabetologia. 2019 Sep;62(Suppl 1):1-600. doi: 10.1007/s00125-019-4946-6. No abstract available.
Reference Type
BACKGROUND
Ma L, Oei L, Jiang L, Estrada K, Chen H, Wang Z, Yu Q, Zillikens MC, Gao X, Rivadeneira F. Association between bone mineral density and type 2 diabetes mellitus: a meta-analysis of observational studies. Eur J Epidemiol. 2012 May;27(5):319-32. doi: 10.1007/s10654-012-9674-x. Epub 2012 Mar 27.
Reference Type
BACKGROUND
Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007 Sep 1;166(5):495-505. doi: 10.1093/aje/kwm106. Epub 2007 Jun 16.
Reference Type
BACKGROUND
Lui DTW, Lee CH, Chan YH, Chow WS, Fong CHY, Siu DCW, Tse HF, Woo YC, Lam KSL. HbA1c variability, in addition to mean HbA1c, predicts incident hip fractures in Chinese people with type 2 diabetes. Osteoporos Int. 2020 Oct;31(10):1955-1964. doi: 10.1007/s00198-020-05395-z. Epub 2020 May 8.
Reference Type
BACKGROUND
Liao CC, Lin CS, Shih CC, Yeh CC, Chang YC, Lee YW, Chen TL. Increased risk of fracture and postfracture adverse events in patients with diabetes: two nationwide population-based retrospective cohort studies. Diabetes Care. 2014 Aug;37(8):2246-52. doi: 10.2337/dc13-2957. Epub 2014 May 7.
Reference Type
BACKGROUND
Yun-Ning Cheung E, Pik-Shan Kong A, Siu-Him Lau E, Yee-Kwan Chow E, On-Yan Luk A, Ching-Wan Ma R, Ping Lam T, Yuk-Wai Lee W, Chun-Yiu Cheng J, Ebeling PR, Chung-Ngor Chan J. Association of hip fractures with cardiometabolic-renal risk factors in Southern Chinese patients with type 2 diabetes - the Hong Kong Diabetes Register. J Diabetes Investig. 2021 Sep;12(9):1739-1748. doi: 10.1111/jdi.13529. Epub 2021 Mar 15.
Reference Type
BACKGROUND
Lecka-Czernik B. Diabetes, bone and glucose-lowering agents: basic biology. Diabetologia. 2017 Jul;60(7):1163-1169. doi: 10.1007/s00125-017-4269-4. Epub 2017 Apr 22.
Reference Type
BACKGROUND
Leslie WD, Aubry-Rozier B, Lamy O, Hans D; Manitoba Bone Density Program. TBS (trabecular bone score) and diabetes-related fracture risk. J Clin Endocrinol Metab. 2013 Feb;98(2):602-9. doi: 10.1210/jc.2012-3118. Epub 2013 Jan 22.
Reference Type
BACKGROUND
Karlson BW, Palmer MK, Nicholls SJ, Lundman P, Barter PJ. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia. Am J Cardiol. 2016 May 1;117(9):1444-8. doi: 10.1016/j.amjcard.2016.02.011. Epub 2016 Feb 17.
Reference Type
BACKGROUND
Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, El-Hajj Fuleihan G, Josse R, Kendler DL, Kraenzlin M, Suzuki A, Pierroz DD, Schwartz AV, Leslie WD; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018 Dec;29(12):2585-2596. doi: 10.1007/s00198-018-4650-2. Epub 2018 Jul 31.
Reference Type
BACKGROUND
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023. Epub 2018 Feb 26.
Reference Type
BACKGROUND
Man LP, Ho AW, Wong SH. Excess mortality for operated geriatric hip fracture in Hong Kong. Hong Kong Med J. 2016 Feb;22(1):6-10. doi: 10.12809/hkmj154568. Epub 2015 Oct 9.
Reference Type
BACKGROUND
Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019 Nov;290:140-205. doi: 10.1016/j.atherosclerosis.2019.08.014. Epub 2019 Aug 31. No abstract available.
Reference Type
BACKGROUND
Oryan A, Kamali A, Moshiri A. Potential mechanisms and applications of statins on osteogenesis: Current modalities, conflicts and future directions. J Control Release. 2015 Oct 10;215:12-24. doi: 10.1016/j.jconrel.2015.07.022. Epub 2015 Jul 28.
Reference Type
BACKGROUND
Moon HJ, Kim SE, Yun YP, Hwang YS, Bang JB, Park JH, Kwon IK. Simvastatin inhibits osteoclast differentiation by scavenging reactive oxygen species. Exp Mol Med. 2011 Nov 30;43(11):605-12. doi: 10.3858/emm.2011.43.11.067.
Reference Type
BACKGROUND
Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab. 2000 Mar;85(3):1137-42. doi: 10.1210/jcem.85.3.6476.
Reference Type
BACKGROUND
Nakashima A, Nakashima R, Ito T, Masaki T, Yorioka N. HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus. Diabet Med. 2004 Sep;21(9):1020-4. doi: 10.1111/j.1464-5491.2004.01292.x.
Reference Type
BACKGROUND
Bouxsein ML, Eastell R, Lui LY, Wu LA, de Papp AE, Grauer A, Marin F, Cauley JA, Bauer DC, Black DM; FNIH Bone Quality Project. Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. J Bone Miner Res. 2019 Apr;34(4):632-642. doi: 10.1002/jbmr.3641. Epub 2019 Jan 23.
Reference Type
BACKGROUND
Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA. 2004 Dec 1;292(21):2585-90. doi: 10.1001/jama.292.21.2585. Epub 2004 Nov 22.
Reference Type
BACKGROUND
Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005 Jun;118(6):618-24. doi: 10.1016/j.amjmed.2005.02.008.
Reference Type
BACKGROUND
Knopp RH, Gitter H, Truitt T, Bays H, Manion CV, Lipka LJ, LeBeaut AP, Suresh R, Yang B, Veltri EP; Ezetimibe Study Group. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J. 2003 Apr;24(8):729-41. doi: 10.1016/s0195-668x(02)00807-2.
Reference Type
BACKGROUND
Mei J, Yeung SS, Kung AW. High dietary phytoestrogen intake is associated with higher bone mineral density in postmenopausal but not premenopausal women. J Clin Endocrinol Metab. 2001 Nov;86(11):5217-21. doi: 10.1210/jcem.86.11.8040.
Reference Type
BACKGROUND
Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. doi: 10.1056/NEJMra070553. No abstract available.
Reference Type
BACKGROUND
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STATIN001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
NCT06938152
RECRUITING
PHASE4
Topic Simvastatin for Bone Regeneration
NCT07031778
RECRUITING
EARLY_PHASE1
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
NCT00043186
COMPLETED
PHASE2
Efficacy and Safety of JMT103 in the Treatment of Postmenopausal Women With Osteoporosis
NCT05278338
UNKNOWN
PHASE2
Risedronate in the Prevention of Osteoporosis in Postmenopausal Women
NCT00402441
COMPLETED
PHASE4
Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients
NCT02156960
UNKNOWN
PHASE4
Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer
NCT00859703
COMPLETED
PHASE3
Safety and Efficacy Study to Evaluate Denosumab Compared With Zoledronic Acid in Postmenopausal Women With Osteoporosis
NCT01732770
COMPLETED
PHASE4
Satisfaction and Compliance of Risedronate in PMO
NCT00549965
COMPLETED
PHASE4
Effects of Phytoestrogen-rich Diets on Bone Turnover in Postmenopausal Women
NCT00301353
COMPLETED
NA
A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.
NCT00330460
COMPLETED
PHASE3
A Randomized, Double-blind, Placebo-controlled, Dose Response Study of AMG 162 (Denosumab) in Japanese Postmenopausal Osteoporotic Subjects
NCT00306189
COMPLETED
PHASE2
Effects of Acute Estrogen Therapy on Bone Formation
NCT02349113
COMPLETED
PHASE1
A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis
NCT00541658
COMPLETED
PHASE3
A Multicenter, Randomized Placebo Controlled Pilot MicroCT Study to Estimate the Effect of Treatment With Denosumab (AMG 162) and Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density
NCT00293813
COMPLETED
PHASE2
A Study of the Treatment of Postmenopausal Women With Osteoporosis
NCT00543023
COMPLETED
PHASE3
A Study of LY2541546 in Women With Low Bone Mineral Density
NCT01144377
COMPLETED
PHASE2
Use of Ibandronate in Diabetic Patients
NCT05266261
COMPLETED
NA
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
NCT00325468
COMPLETED
PHASE3
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
NCT00557310
COMPLETED
PHASE4
Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis
NCT00439244
COMPLETED
PHASE3
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
NCT00927186
COMPLETED
PHASE4
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
NCT05405725
UNKNOWN
PHASE3
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
NCT07242612
RECRUITING
NA